Subtype
Intrahepatic Cholangiocarcinoma
CI-CAN-00002944ICC · ICCAExplore in graph →
86 active trials1 approved drugs8 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002944ICC · ICCAExplore in graph →
Variants & evidence
13 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E2 | ||||||||
| Dabrafenib + TrametinibCombination | Intrahepatic Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID5903Two cases of patients with BRAF V600E positive, refractory intrahepatic cholangiocarcinoma showed excellent clinical and radiographic response to combination dabrafenib and trametinib treatment. One p… (full text at CIViC) PMID 28078132 · Lavingia et al., 2016 · Open in CIViC | civic |
| 〃 | Intrahepatic Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID5904Dabrafenib and trametinib combination showed durable response for a patient with standard chemotherapy and radiation refractory, poorly differentiated, intrahepatic cholangiocarcinoma harboring BRAF V… (full text at CIViC) PMID 25435907 · Loaiza-Bonilla et al., 2014 · Open in CIViC | civic |
| ACOT11 Fusion1 | ||||||||
| Erdafitinib | Intrahepatic Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID13163In the phase II NCI-MATCH EAY131-K2 trial, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-ACOT11 fusion achieved a partial response to erdafitinib, with a 49.6% maximum reduction in… (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC | civic |
| AHCYL1 Fusion1 | ||||||||
| Erdafitinib | Intrahepatic Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID13164In the phase II NCI-MATCH EAY131-K2 trial, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-AHCYL1 fusion achieved a partial response to erdafitinib, with a 66.7% maximum reduction in… (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC | civic |
| BICC1 Fusion1 | ||||||||
| Futibatinib | Intrahepatic Cholangiocarcinoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID11610In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC | civic |
| KIAA1217 Fusion1 | ||||||||
| Futibatinib | Intrahepatic Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11611In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC | civic |
| FGFR2 Fusion + FGFR2 Fusion4 | ||||||||
| Derazantinib | Intrahepatic Cholangiocarcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID7329Actionable fibroblast growth factor receptor 2 (FGFR2) fusions have been identified in intrahepatic cholangiocarcinomas (iCCA). Derazantinib, a multi-kinase inhibitor with potent pan-FGFR activity sho… (full text at CIViC) PMID 30420614 · Mazzaferro et al., 2019 · Open in CIViC | civic |
| Futibatinib | Intrahepatic Cholangiocarcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11609In the phase 2 trial (NCT02052778), 103 patients (22-79 years of age) with unresectable or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements were treated with the … (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC | civic |
| 〃 | Intrahepatic Cholangiocarcinoma | Predictive | B | Supports | ||||
| FGFR2 Y376C1 | ||||||||
| AZD-4547 | Intrahepatic Cholangiocarcinoma | Predictive | C | Does Not Support Sensitivity Response | 1 | submitted | EID8317The phase II NCI-MATCH trial (EAY131) subprotocol W assessed the FGFR1-3 selective TKI AZD-4547 in 48 patients with FGFR1/2 amplifications, FGFR2/3 SNV or FGFR1/3 fusions. The partial response overall… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC | civic |
| GNAS c.393T>C1 | ||||||||
| (prognostic) | Intrahepatic Cholangiocarcinoma | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1996Intrahepatic cholangiocarcinomas of patients with homozygous TT genotypes revealed a higher proliferation rate and a lower apoptotic rate.This study demonstrated a significant association of both dise… (full text at CIViC) PMID 17356712 · Schmitz et al., 2007 · Open in CIViC | civic |
| IDH1 R1321 | ||||||||
| Dasatinib | Intrahepatic Cholangiocarcinoma | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID6439Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tract cancers, this work found that IDH mutant (IDHm) ICC cells demonstrate a striking response to the… (full text at CIViC) PMID 27231123 · Saha et al., 2016 · Open in CIViC | civic |
Data updated 21 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| 3 |
| submitted |
EID11612In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC |
| civic |
| Pemigatinib | Cholangiolocellular Small Duct Intrahepatic CholangiocarcinomaALIAS | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID8173In a multicentre, open-label, single-arm, phase 2 study (FIGHT-202), patients with disease progression following at least one previous treatment received a starting dose of 13·5 mg oral pemigatinib on… (full text at CIViC) PMID 32203698 · Abou-Alfa et al., 2020 · Open in CIViC | civic |